Table of Contents

2019-2024 Global Drugs for Schistosomiasis Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Drugs for Schistosomiasis Consumption 2014-2024
  • 2.1.2 Drugs for Schistosomiasis Consumption CAGR by Region
• 2.2 Drugs for Schistosomiasis Segment by Type
  • 2.2.1 Praziquantel
  • 2.2.2 Oxamniquine
  • 2.2.3 Other
• 2.3 Drugs for Schistosomiasis Consumption by Type
  • 2.3.1 Global Drugs for Schistosomiasis Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Drugs for Schistosomiasis Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Drugs for Schistosomiasis Sale Price by Type (2014-2019)
• 2.4 Drugs for Schistosomiasis Segment by Application
  • 2.4.1 S. haematobium
  • 2.4.2 S. mansoni
  • 2.4.3 S. japonicum
  • 2.4.4 S. mekongi
  • 2.4.5 S. intercalatum
• 2.5 Drugs for Schistosomiasis Consumption by Application
  • 2.5.1 Global Drugs for Schistosomiasis Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Drugs for Schistosomiasis Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Drugs for Schistosomiasis Sale Price by Application (2014-2019)

3 Global Drugs for Schistosomiasis by Players

• 3.1 Global Drugs for Schistosomiasis Sales Market Share by Players
  • 3.1.1 Global Drugs for Schistosomiasis Sales by Players (2017-2019)
  • 3.1.2 Global Drugs for Schistosomiasis Sales Market Share by Players (2017-2019)
• 3.2 Global Drugs for Schistosomiasis Revenue Market Share by Players
  • 3.2.1 Global Drugs for Schistosomiasis Revenue by Players (2017-2019)
  • 3.2.2 Global Drugs for Schistosomiasis Revenue Market Share by Players (2017-2019)
• 3.3 Global Drugs for Schistosomiasis Sale Price by Players
• 3.4 Global Drugs for Schistosomiasis Manufacturing Base Distribution, Sales Area, Product Types by Players
  • 3.4.1 Global Drugs for Schistosomiasis Manufacturing Base Distribution and Sales Area by Players
  • 3.4.2 Players Drugs for Schistosomiasis Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Drugs for Schistosomiasis by Regions

• 4.1 Drugs for Schistosomiasis by Regions
  • 4.1.1 Global Drugs for Schistosomiasis Consumption by Regions
  • 4.1.2 Global Drugs for Schistosomiasis Value by Regions
• 4.2 Americas Drugs for Schistosomiasis Consumption Growth
• 4.3 APAC Drugs for Schistosomiasis Consumption Growth
• 4.4 Europe Drugs for Schistosomiasis Consumption Growth
• 4.5 Middle East & Africa Drugs for Schistosomiasis Consumption Growth

5 Americas

• 5.1 Americas Drugs for Schistosomiasis Consumption by Countries
  • 5.1.1 Americas Drugs for Schistosomiasis Consumption by Countries (2014-2019)
  • 5.1.2 Americas Drugs for Schistosomiasis Value by Countries (2014-2019)
• 5.2 Americas Drugs for Schistosomiasis Consumption by Type
• 5.3 Americas Drugs for Schistosomiasis Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Drugs for Schistosomiasis Consumption by Countries
  • 6.1.1 APAC Drugs for Schistosomiasis Consumption by Countries (2014-2019)
  • 6.1.2 APAC Drugs for Schistosomiasis Value by Countries (2014-2019)
• 6.2 APAC Drugs for Schistosomiasis Consumption by Type
• 6.3 APAC Drugs for Schistosomiasis Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Drugs for Schistosomiasis by Countries
  • 7.1.1 Europe Drugs for Schistosomiasis Consumption by Countries (2014-2019)
  • 7.1.2 Europe Drugs for Schistosomiasis Value by Countries (2014-2019)
• 7.2 Europe Drugs for Schistosomiasis Consumption by Type
• 7.3 Europe Drugs for Schistosomiasis Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Drugs for Schistosomiasis by Countries
  • 8.1.1 Middle East & Africa Drugs for Schistosomiasis Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Drugs for Schistosomiasis Value by Countries (2014-2019)
• 8.2 Middle East & Africa Drugs for Schistosomiasis Consumption by Type
• 8.3 Middle East & Africa Drugs for Schistosomiasis Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 Drugs for Schistosomiasis Distributors
• 10.3 Drugs for Schistosomiasis Customer

11 Global Drugs for Schistosomiasis Market Forecast

• 11.1 Global Drugs for Schistosomiasis Consumption Forecast (2019-2024)
• 11.2 Global Drugs for Schistosomiasis Forecast by Regions
  • 11.2.1 Global Drugs for Schistosomiasis Forecast by Regions (2019-2024)
  • 11.2.2 Global Drugs for Schistosomiasis Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Drugs for Schistosomiasis Forecast by Type
• 11.8 Global Drugs for Schistosomiasis Forecast by Application

12 Key Players Analysis

• 12.1 Shin Poong
  • 12.1.1 Company Details
  • 12.1.2 Drugs for Schistosomiasis Product Offered
  • 12.1.3 Shin Poong Drugs for Schistosomiasis Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 Shin Poong News
• 12.2 Merck
  • 12.2.1 Company Details
  • 12.2.2 Drugs for Schistosomiasis Product Offered
  • 12.2.3 Merck Drugs for Schistosomiasis Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 Merck News
• 12.3 Bayer
  • 12.3.1 Company Details
  • 12.3.2 Drugs for Schistosomiasis Product Offered
  • 12.3.3 Bayer Drugs for Schistosomiasis Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Bayer News
• 12.4 EIPICO
  • 12.4.1 Company Details
  • 12.4.2 Drugs for Schistosomiasis Product Offered
  • 12.4.3 EIPICO Drugs for Schistosomiasis Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 EIPICO News
• 12.5 Chandra Bhagat Pharma
  • 12.5.1 Company Details
  • 12.5.2 Drugs for Schistosomiasis Product Offered
  • 12.5.3 Chandra Bhagat Pharma Drugs for Schistosomiasis Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 Chandra Bhagat Pharma News
• 12.6 Taj Pharmaceuticals
  • 12.6.1 Company Details
  • 12.6.2 Drugs for Schistosomiasis Product Offered
  • 12.6.3 Taj Pharmaceuticals Drugs for Schistosomiasis Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.6.4 Main Business Overview
  • 12.6.5 Taj Pharmaceuticals News

...

13 Research Findings and Conclusion

Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.
The global average price of Drugs for Schistosomiasis is in the decreasing trend, from 62 USD/K Units in 2011 to 57 USD/K Units in 2015. With the situation of global economy, prices will be in decreasing trend in the following five years.
The classification of Drugs for Schistosomiasis is Praziquantel, Oxamniquine and other. Praziquantel is the mainly drug for Schistosomiasis, and the proportion of Praziquantel in 2015 is about 90%.
Drugs for Schistosomiasis are widely used in S. haematobium, S. mansoni, S. japonicum, S. mekongi and S. intercalatum.Most of human infections are caused by S. haematobium, S. mansoni, S. japonicum. And the market share used in S. haematobium in 2015 is 28%. And the market share used in S. mansoni in 2015 is 48%.

According to this study, over the next five years the Drugs for Schistosomiasis market will register a 5.6% CAGR in terms of revenue, the global market size will reach US$ 100 million by 2024, from US$ 70 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Drugs for Schistosomiasis business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Schistosomiasis market by product type, application, key manufacturers and key regions and countries.

This study considers the Drugs for Schistosomiasis value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Praziquantel
Oxamniquine
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
S. haematobium
S. mansoni
S. japonicum
S. mekongi
S. intercalatum

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Shin Poong
Merck
Bayer
EIPICO
Chandra Bhagat Pharma
Taj Pharmaceuticals
...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Drugs for Schistosomiasis consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Drugs for Schistosomiasis market by identifying its various subsegments.
Focuses on the key global Drugs for Schistosomiasis manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Drugs for Schistosomiasis with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Drugs for Schistosomiasis submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.